Brian R. Overholser
2001 PharmD, Purdue University
1997 Pre-Pharmacy, Purdue University
My research program is focused on the clinical pharmacology of cardiovascular drugs. The overall goal is to enhance the understanding of pathophysiological mechanisms and pharmacological factors influencing the response variability to cardiovascular active agents.
PHRM 403, Integrated Laboratory IV
PHRM 847, Principles of Pharmacogenomics
PHPR 312, Introduction to Pharmacy and Pharmaceutical Care
PHPR 698, Graduate Research
CLPH 490N, Introduction to Clinical Research
CLPH 585, Adult Medicine
CLPH 589, Clinical Research
CLPH 690, Pharmacokinetics
CLPH 696, Graduate Seminar
PHAD 660, Grant Writing
IPPH 575, Clinical Pharmacokinetics and Biopharmaceutics II
MCMP 311, Biometrics and Pharmaceutical Analysis
Honors and Credentials
Best Paper Award for Circulation: Cardiovascular Quality and Outcomes. 2014; 7(3): 381-90. Cardiology PRN, American College of Clinical Pharmacy
Health Sciences Research Award, Indiana Public Health Foundation
Fellow of the American College of Clinical Pharmacy (FCCP)
New Investigator Award, American College of Clinical Pharmacy
Faculty Fellowship for Study in a Second Discipline, Office of the Provost, Purdue University
Young Investigator Travel Award, Cardiology PRN, American College of Clinical Pharmacy
Fellowship in the Biomedical Sciences, American Foundation for Pharmaceutical Education
M. Kelli Jordan Award, PK/PD PRN, American College of Clinical Pharmacy
Best Paper by Student, Resident, or Fellow (runner-up), American College of Clinical Pharmacy
Aventis Pharmaceuticals Infectious Diseases Fellowship, American College of Clinical Pharmacy
1. Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ. Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. JACC; Clinical Electrophysiology. 2016 Dec:2(7);765-774.
2. Wang X, Wang H, Shen B, Overholser BR, Cooper BR, Lu Y, Tang H, Zhou C, Sun X, Zhong L, Favus MJ, Decker BS, Liu W, Peng Z. 1-alpha, 25-dihydroxyvitamin D3 Regulates Two Intestinal UDP-glucuronosyltransferases 1A8 and 1A10 and Alters the Pharmacokinetics of Mycophenolic Acid. Transl Res. 2016 Dec;178:54-62.
3. Melton BL, Zillich AJ, Saleem J, Russ AL, Tisdale JE, Overholser BR. Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing. Appl Clin Inform. 2016 Nov 23;7(4):1088-1106.
4. Abdelhady AM, Shugg T, Thong N, Lu JB, Kreutz Y, Jaynes HA, Robarge JD, Tisdale JE, Desta Z, Overholser BR. Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. J Cardiovasc Electrophysiol. 2016 Oct;27(10):1206-1213.
5. Tisdale JE, Allen MR, Overholser BR, Jaynes HA, Kovacs RJ. Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements. J Cardiovasc Electrophysiol. 2015 Jun;26(6):671-7.
6. Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs RJ. Effectiveness of a Clinical Decision Support System for Reducing the Risk of QT Interval Prolongation in Hospitalized Patients. v. Circulation: Cardiovascular Quality and Outcomes. 2014; 7(3): 381-90.
7. Pergolizzi JV, Ma L, Foster DR, Overholser BR, Sowinski KM, Taylor Jr, R, Summers KH. The Prevalence of Opioid-Related Major Potential Drug-Drug Interactions and their Impact on Healthcare Costs in Chronic Pain Patients. Journal of Managed Care Pharmacy. 2014; 20(5): 467-76.
8. Abdelhady AM, Desta Z, Jiang F, Yeo CW, Shin JG, Overholser BR. Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. Journal of Clinical Pharmacology. 2014. 54(1): 87-96.
9. Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs RJ. Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients. Circulation: Cardiovascular Quality and Outcomes. 2013: 6(4); 479-87.
10. Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, Tisdale JE, Overholser BR. Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: A novel approach to guide renal dose adjustments. American Journal of Kidney Diseases. 2013: 61(6); 1046-8.